PartoSure
The PartoSure Test is CE marked and is currently investigational use only in the United States. Parsagen Diagnostics, Inc. is the manufacturer of PartoSure, a novel bedside test to aid in the assessment of preterm delivery in patients with symptoms of preterm labor. Based on the detection of PAMG-1, PartoSure has been shown in published studies to have a higher positive predictive value compared to current methods, while maintaining an equally high negative predictive value. Preterm birth has proven to be a major diagnostic challenge, until now. Clinical evaluation alone, including the measurement of cervical length and dilatation, is not sufficiently predictive of imminent delivery among patients with signs of threatened preterm labour. Similarly, currently available biomarker tests, such as that which is based on the detection of fetal fibronectin (fFN), have extremely poor positive predictive values for imminent delivery. Because of this, 85% of patients admitted to the hospital for threatened preterm labour do not even deliver within the next 7 days, costing hospitals up to 8,000 . However, the PartoSure test has proven to be a superior test for assessing a patient's risk for preterm birth across various studies and geographies. The test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labour. PartoSures unique features include: High Positive (PPV) and Negative Predictive Value (NPV); usable shortly after vaginal exam; speculum examination optional; results in 5 minutes or less; no special equipment or training needed; wide gestational age range from 20 to 37 weeks. The test is most useful in cases where cervical length (CL) is between 15 and 30 mm where the predictive value of CL is lowest. While a CL-cutoff of 25 mm is often utilized, up to 1 in 8 women with a CL between 25-30 mm will deliver within the next 7 days.
PartoSure
The PartoSure Test is CE marked and is currently investigational use only in the United States. Parsagen Diagnostics, Inc. is the manufacturer of PartoSure, a novel bedside test to aid in the assessment of preterm delivery in patients with symptoms of preterm labor. Based on the detection of PAMG-1, PartoSure has been shown in published studies to have a higher positive predictive value compared to current methods, while maintaining an equally high negative predictive value. Preterm birth has proven to be a major diagnostic challenge, until now. Clinical evaluation alone, including the measurement of cervical length and dilatation, is not sufficiently predictive of imminent delivery among patients with signs of threatened preterm labour. Similarly, currently available biomarker tests, such as that which is based on the detection of fetal fibronectin (fFN), have extremely poor positive predictive values for imminent delivery. Because of this, 85% of patients admitted to the hospital for threatened preterm labour do not even deliver within the next 7 days, costing hospitals up to 8,000 . However, the PartoSure test has proven to be a superior test for assessing a patient's risk for preterm birth across various studies and geographies. The test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labour. PartoSures unique features include: High Positive (PPV) and Negative Predictive Value (NPV); usable shortly after vaginal exam; speculum examination optional; results in 5 minutes or less; no special equipment or training needed; wide gestational age range from 20 to 37 weeks. The test is most useful in cases where cervical length (CL) is between 15 and 30 mm where the predictive value of CL is lowest. While a CL-cutoff of 25 mm is often utilized, up to 1 in 8 women with a CL between 25-30 mm will deliver within the next 7 days.
partosure.com
114 Western Avenue Harvard Launch Labs Boston, MA 02134, US
Details
Year founded
2012
Revenue
1M-5M
Employees
11-50
Number of locations
1
NAICS
3391
SIC
3841
Products & Services
Outlines the company's specialized services and operational strengths.
- PartoSure Test
- Contact us in order to access
Equipment
Provides a detailed list of machinery and tools utilized on the company's premises.
- PartoSure test - rapid, qualitative test for detecting the presence of placental alpha microglobulin 1 (PAMG-1) in cervicovaginal secretions
- Contact us in order to access
Ramping up production
Indicates the company's current production trend and growth trajectory.
FALSE
Our production algorithm is showing that partosure is not ramping up production.
Target industries
Locations (1)
PartoSure
114 Western Avenue Harvard Launch Labs Boston, MA 02134, US
Frequently Asked Questions
What services & capabilities does PartoSure offer?
PartoSure offers a range of services and capabilities, including PartoSure Test.
What kind of equipment does PartoSure use?
PartoSure uses a variety of equipment, including PartoSure test - rapid, qualitative test for detecting the presence of placental alpha microglobulin 1 (PAMG-1) in cervicovaginal secretions.
What are the target industries of PartoSure?
PartoSure serves several industries, including the medical industry.
How many locations does PartoSure operate?
PartoSure operates from a single location at 114 western avenue harvard launch labs, boston, massachusetts 02134, united states.
Where are the headquarters of PartoSure?
The headquarters of PartoSure are located in 114 western avenue harvard launch labs, boston, massachusetts 02134, united states.
What is the NAICS code for PartoSure?
The NAICS code for PartoSure is 3391.
How many employees does PartoSure have?
PartoSure has an employee count in the range of 11-50 employees.
What is the official website of PartoSure?
The official website of PartoSure is https://www.partosure.com/.
When was PartoSure founded?
PartoSure was founded in 2012.